DJIA 17,776.12 -200.19 -1.11%
NASDAQ 4,900.89 -46.56 -0.94%
S&P 500 2,067.89 -18.35 -0.88%
market minute promo

4.37 -0.11 (-2.46%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ARNA $4.37 -2.46%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.46
Previous Close $4.48
Daily Range $4.37 - $4.60
52-Week Range $3.26 - $7.22
Market Cap $1.1B
P/E Ratio -16.00
Dividend (Yield) $0.00 (0.0%)
Volume 2,286,638
Average Daily Volume 5,322,236
Current FY EPS -$0.54

Sector

Healthcare

Industry

Drug Makers

Arena Pharmaceuticals, Inc. (ARNA) Description

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Website: http://www.arenapharm.com/

News & Commentary Rss Feed

Biotech Stocks: 2 to Avoid, 1 to Buy

Motley Fool contributor Todd Campbell offers insight on three biotech stocks, including two that investors should stay away from.

Arena - Assessing Belviq In South Korea

Orexigen Will Make The Obesity Space A Two-Product Race

Arena: Belviq Sales Flatter Than Needed - Q1 Revenue Miss Likely

Arena Investors Need To Pay Attention To Competition

ARNA Crosses Below Key Moving Average Level

Orexigen: Contrave Gathering Momentum

Vivus, Arena, Or Orexigen - Which Will Win The Anti-Obesity Market Share Race?

Orexigen - Contrave Scripts Up, Equity Down, Approval In Europe Still Not Announced

Arena: Belviq Scripts See Modest Rise, Revenue Story Not Promising

See More ARNA News...

ARNA's Top Competitors

ARNA $4.37 (-2.46%)
Current stock: ARNA
AMGN $159.85 (-2.71%)
Current stock: AMGN
GILD $98.13 (-2.54%)
Current stock: GILD
BIIB $422.24 (-2.17%)
Current stock: BIIB